학술논문

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
Document Type
article
Source
Nature Communications. 14(1)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Human Genome
Lung
Biotechnology
Cancer
Genetics
Rare Diseases
Lung Cancer
Aetiology
2.1 Biological and endogenous factors
Animals
Humans
Mice
Adenocarcinoma of Lung
CCAAT-Enhancer-Binding Proteins
Cell Transformation
Neoplastic
DNA Methylation
Epigenesis
Genetic
Lung Neoplasms
Proto-Oncogene Proteins p21(ras)
Ubiquitin-Protein Ligases
Language
Abstract
KRAS is a frequent driver in lung cancer. To identify KRAS-specific vulnerabilities in lung cancer, we performed RNAi screens in primary spheroids derived from a Kras mutant mouse lung cancer model and discovered an epigenetic regulator Ubiquitin-like containing PHD and RING finger domains 1 (UHRF1). In human lung cancer models UHRF1 knock-out selectively impaired growth and induced apoptosis only in KRAS mutant cells. Genome-wide methylation and gene expression analysis of UHRF1-depleted KRAS mutant cells revealed global DNA hypomethylation leading to upregulation of tumor suppressor genes (TSGs). A focused CRISPR/Cas9 screen validated several of these TSGs as mediators of UHRF1-driven tumorigenesis. In vivo, UHRF1 knock-out inhibited tumor growth of KRAS-driven mouse lung cancer models. Finally, in lung cancer patients high UHRF1 expression is anti-correlated with TSG expression and predicts worse outcomes for patients with KRAS mutant tumors. These results nominate UHRF1 as a KRAS-specific vulnerability and potential target for therapeutic intervention.